The combination of metronomic taxanes and valproic acid and enoxaparin decreases tumour marker levels in taxane refractory tumour types: a single arm, single centre, non-randomised, phase II feasibility trial

St Mary Hospital (Sint-Maria Ziekenhuis) (Belgium)0 个研究点目标入组 24 人开始时间: 2009年8月27日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Histologically or cytologically proven metastatic solid tumours. Patients must have disease which has failed standard taxane based chemotherapy.
•2. Greater than or equal to 18 years of age, either sex
•3. Eastern Cooperative Oncology Group performance status (ECOG PS) less than or equal to 3
•4. Life expectancy greater than or equal to 8 weeks
•5. Evaluable (based on radiological assessments or tumour markers) disease
•6. Recovered (i.e., to National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] Version 3.0 Grade less than or equal to 1) from all toxicities associated with previous chemotherapy or radiotherapy (exception: patients may enter with continuing alopecia irrespective of CTCAE grade). The following intervals between starting last treatment must elapse:
•6.1. Chemotherapy: at least 4 weeks
•6.2. Mitomycin C or a nitrosourea: at least 6 weeks
•6.3. Targeted therapy: at least 2 weeks or 2 half-lives, whichever is longer
•6.4. Biologics: at least 4 weeks

•1. Pregnant women, women who are lactating, or women of childbearing potential who are not currently on effective means of birth control
•2. History of QT/QTc prolongation, clinically significant ventricular tachycardia, ventricular fibrillation, heart block, myocardial infarction within 1 year, congestive heart failure New York Heart Association Class III or IV, unstable angina, angina within 6 months, or other evidence of clinically significant coronary artery disease
•3. Active, ongoing infection, including viral hepatitis
•4. Undergone major surgery within the last 4 weeks
•5. Organ transplant recipients
•6. New brain metastasis. Patients with treated (surgically excised or irradiated) and stable brain metastases are eligible as long as the treatment was at least 4 weeks prior to initiation of study drug and baseline brain computed tomography (CT) with contrast or magnetic resonance imaging (MRI) within 2 weeks of initiation of study drug is negative for new brain metastases.
•7. Patients who have been on other experimental clinical trials of investigational agents within the last 28 days

发起方

St Mary Hospital (Sint-Maria Ziekenhuis) (Belgium)